This message has been cross posted to the following Discussions: Decision Analysis Society and INFORMS Open Forum .
-------------------------------------------
Many solutions had been proposed by stakeholders from professional groups, academia and government to reinvigorate antibiotic drug development and address the emerging threat of infection posed by drug-resistant pathogens. This presentation illustrates how decision analysis clarified what solutions would address the problems most effectively and aligned stakeholders to rally support for specific changes in public policy that would have the most impact towards stimulating antibiotic development. President Obama signed the Generating Antibiotic Incentives Now Act (i.e., GAIN Act)
This webinar is hosted by the Society of Decision Professionals. Use the link below to read more or register.
Date: June 17, 8:30 - 9:45 a.m. Pacific Time
Title: Portfolio & Decision Analysis and The Fight Against Antimicrobial Resistance
Register: REGISTER HERE
Featured Speaker:
Jon Mauer works in Pfizer’s Portfolio & Decision Analysis (PDA) group. He has 18 years of industry experience at Pfizer and Bristol-Myers Squibb. Before joining the pharmaceutical industry, he practiced pharmacy at Beth Israel Medical Center.
Moderator:
Elayne Ko currently holds a Director position at the Portfolio and Decision Analysis (PDA) group within Pfizer, Inc. She has over 15 years of experience in applying decision analysis to investment decision-making under uncertainties.
Questions? Contact: Hilda Cherekdjian
Executive Director
Society of Decision Professionals
hilda@decisionprofessionals.com
Posted by:
Carl Spetzler
CEO
Strategic Decisions Group
Palo Alto CA
------------------------------